The spatial arrangement of DNA can shape the characteristics of blood cancer

Research team has demonstrated how certain gene mutations alter the 3D structure of DNA and can thereby activate cancer-related genes in leukemia cells

18-Nov-2026
© Kathrin Richter, UKSH

Dr Sophie Steinhäuser, together with her colleagues, was able to demonstrate that in AML with IDH1 and DNMT3A mutations, there is an abnormal spatial organisation of the DNA, which is responsible for the activation of cancer-related signalling pathways.

acute myeloid leukemia (AML) is a malignant disorder of the hematopoietic system in the bone marrow, affecting an early precursor stage of what are known as myeloid cells. In healthy people, these cells develop into red blood cells, platelets and some white blood cells – a process that is normally strictly regulated. In people with the disease, however, these cells exhibit genetic alterations that cause them to multiply uncontrollably in the bone marrow, where they increasingly displace the healthy blood cells. This ultimately impairs the vital functions of the hematopoietic system. The causes of the disease have not yet been fully elucidated and may be linked to various genetic changes, some of which can be acquired over the course of a person’s life.

Researchers from the Faculty of Medicine at Kiel University, the Department of Internal Medicine II – Hematology and Oncology at the UKSH, Campus Kiel, the Institute of Human Genetics at UKSH, Campus Lübeck, the Institute of Medical Genetics and Human Genetics at Charité - Universitätsmedizin Berlin, and the Max Planck Institute for Molecular Genetics in Berlin/Dahlem have now published a joint paper: In this study, they investigated how two common alterations in regulatory genes - mutations in IDH1 and DNMT3A - influence the three-dimensional organization of the genome in leukemia cells. The researchers were able to demonstrate that both mutations interfere with the spatial arrangement of DNA in different ways and that these changes are associated with altered activity in numerous genes, which varies depending on the mutation. This global regulatory mechanism in AML was previously unknown. The new findings by the researchers led by Professor Claudia Baldus of the „Kiel Oncology Network“ (KON) and the University cancer Centre Schleswig-Holstein (UCCSH), and Professor Malte Spielmann, Head of the Institute of Medical Genetics and Human Genetics at Charité Berlin, were recently published in the journal Leukemia. The German José Carreras Leukemia Foundation, amongst others, had funded the underlying research.

DNA is not just a linear blueprint

A cell’s genetic information does not simply exist as a long, linear strand of DNA. Within the cell nucleus, the DNA is folded in complex ways and organized spatially. As a result, certain sections of DNA can come into contact with one another, even though they are located far apart on the linear DNA strand. Among other things, such contacts influence which genes and signaling pathways are currently active in a cell. So-called CTCF-binding proteins play an important role in this process. They can link distant regions of the DNA, thereby forming a loop from the DNA lying between them. This spatial organization can, for example, help ensure that regulatory DNA regions come into contact with specific genes in a targeted manner, whilst other regions remain isolated from one another.

It was already known from previous research that mutations in IDH1 and DNMT3A are associated with changes in DNA methylation. This refers to the chemical modification of DNA which, in healthy people, selectively switches certain genes on or off, thereby regulating the amount of protein produced from them. The current study now shows that these methylation changes can also occur at the binding sites of CTCF proteins and, in this way, disrupt the formation of DNA loops, leading to a global reorganization of the three-dimensional structure of the DNA. “Our results show that both mutations influence the spatial organization of the genome,” explains Dr Sophie Steinhäuser, a research associate in the Functional Genomics of Acute Leukemia research group and first author of the study. “The changes differ between AML cells with IDH1 and DNMT3A mutations, suggesting that each genetic alteration apparently gives rise to its own characteristic 3D structure.” In cell models and patient samples, the researchers identified thousands of altered DNA loops for each of the two mutations. The more these loops were altered, the more pronounced the change in gene activity was. The researchers developed their own analytical method specifically for their multi-stage investigation of the complex 3D structural data and gene expression data. “This now enables us to correlate genome-wide differences in DNA looping with global changes in gene expression,” emphasizes Dr Varun Sreenivasan, a research fellow in the Molecular Human Genetics group at the Max Planck Institute Berlin/Dahlem and also first author.


Different molecular patterns result in different responses to treatment

These 3D changes result in far-reaching alterations in gene activation and, consequently, in the active signaling pathways, which are specific to each mutation. In AML cells with a DNMT3A mutation, the researchers found, amongst other things, alterations in signaling pathways associated with resistance to tyrosine kinase inhibitors, whilst in AML with an IDH1 mutation, signaling pathways linked to the cells’ immune response are affected.  

One particularly striking example was the IGF1R gene. The researchers were able to clearly demonstrate, both in the cell model and in samples from patients, that this gene is located within an altered loop and exhibits significantly increased activation in IDH1-mutated cells. To determine whether targeted inhibition of IGF1R could be a potential treatment option for IDH1-mutated AML, the researchers not only compared drug response data from previously published studies but also investigated IGF1R sensitivity in the cell model. The results indeed showed that both patient data and IDH1-mutated AML cells exhibited greater sensitivity to this drug than cells without an IDH1 mutation. BMS-754807 also demonstrated a synergistic effect when combined with the IDH1 inhibitor Ivosidenib, which is used in clinical practice.  

As with IDH1, the researchers also identified the p38/MAPK inhibitor Ralimetinib as a potential therapeutic option from samples and cell models of AML with DNMT3A mutations. “Overall, our work provides a comprehensive map of the changes in 3D DNA organization in AML with IDH1 and DNMT3A mutations,” emphasizes Baldus, head of the Functional Genomics of Acute Leukemia research group at Kiel University’s Medical Faculty and director of the Department of Internal Medicine at UKSH in Kiel. “The genes and signaling pathways identified thus open up new avenues for the development of novel targeted therapies.”

Original publication

Other news from the department science

Most read news

More news from our other portals